GTI-2040 and Gemcitabine in Treating Patients With Metastatic or Unresectable Solid Tumors

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 31, 2004

Primary Completion Date

November 30, 2007

Conditions

Unspecified Adult Solid Tumor, Protocol Specific

Interventions

BIOLOGICAL

GTI-2040

Given IV

DRUG

gemcitabine hydrochloride

Given IV

OTHER

laboratory biomarker analysis

Correlative studies

OTHER

pharmacological study

Correlative studies

Trial Locations (1)

Cancer Therapy and Research Center at The UT Health Science Center at San Antonio, San Antonio

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH

NCT00078962 - GTI-2040 and Gemcitabine in Treating Patients With Metastatic or Unresectable Solid Tumors | Biotech Hunter | Biotech Hunter